Abstract
VEGF-A and FGF-2 are two angiogenic growth factors involved in the growth and invasion of solid tumours and haematological malignancies. They are also believed to play an important role in cardiovascular and inflammatory diseases. Several studies dealing with measurement of circulating FGF-2 and VEGF have been published during the last decade. We have studied the levels of FGF-2 and VEGF-A in serum and EDTA plasma from 80 healthy blood donors. The samples were analyzed using the most widely used and commercially available ELISAkits. There was no significant effect of age on any of the assays and no effect of sex on P-FGF-2, S-VEGF-A and P-VEGF-A. Using the 97.5th percentile we obtained the following reference values: P-FGF-2 <6.4 ng/l; S-VEGF-A <500 ng/l; P-VEGF-A <80 ng/l. Separate gender based reference intervals were made for S-FGF-2 as women had significantly higher S-FGF-2 values. Reference values for S-FGF-2 were <4.0 ng/l (men) and <10.8 ng/l (women).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175: 409–16.
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.
Perez-Atayde AR, Sallan SE, Tedrow U et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815–21.
Skoldenberg EG, Christiansson J, Sandstedt B et al. Angiogenesis and angiogenic growth factors in Wilms tumor. J Urol 2001; 165: 2274–9.
Dirix LY, Vermeulen PB, Pawinski A et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238–43.
Shijubo N, Uede T, Kon S et al. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog 2000; 11: 135–46.
Haynes LW. Fibroblast (heparin-binding) growing factors in neuronal development and repair. Mol Neurobiol 1988; 2: 263–89.
Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc Natl Acad Sci USA 1991; 88: 11007–11.
Poole TJ, Finkelstein EB, Cox CM. The role of FGF and VEGF in angioblast induction and migration during vascular development. Dev Dyn 2001; 220: 1–17.
Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–5.
Brock TA, Dvorak HF, Senger DR. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991; 138: 213–21.
Carmeliet P, Moons L, Dewerchin M et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann NY Acad Sci 1997; 811: 191–206.
Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol 2000; 34: 185–94.
Clauss M, Gerlach M, Gerlach H et al. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535–45.
Kuroi K, Toi M. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 2001; 16: 5–26.
Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505–15.
Dittadi R, Meo S, Fabris F et al. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 2001; 16: 87–96.
Lee JK, Hong YJ, Han CJ et al. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen? Int J Oncol 2000; 17: 149–52.
Banks RE, Forbes MA, Kinsey SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956–64.
Chodak GW, Scheiner CJ, Zetter BR. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. N Engl J Med 1981; 305: 869–74.
Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001; 47: 617–23.
Bienvenu JA, Coulon L, Doche C et al. Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNF-alpha. A WHO study. Eur Cytokine Netw 1993; 4: 447–51.
Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Larsson, A., Sköldenberg, E. & Ericson, H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis 5, 107–110 (2002). https://doi.org/10.1023/A:1021588227705
Issue Date:
DOI: https://doi.org/10.1023/A:1021588227705